All articles by Manasi Vaidya

Manasi Vaidya is the lead editor for Pharmaceutical Technology where she covers the healthcare space. She writes features that look at the research, regulation and reimbursement of drugs with a focus on topics at the intersection of business and science. She is based in Brooklyn and an alum of New York University’s Science, Health and Environmental Reporting program.

Manasi Vaidya

@manasivaidya22

Magazine: What Rishi Sunak can do for the UK pharma industry

In this issue: The UK pharma sector’s wishlist for the new PM, the difficult outlook for chronic cardiovascular drug shortages, assessing the value of hemophilia gene therapies, and more

Early cell therapy successes start to turn the tide in lupus

CAR-Ts and MSCs are showing encouraging efficacy signals in treating lupus at a time when conventional approaches could also make a dent.

Magazine: Medicine in outer space

In this issue: Drug development and manufacturing in outer space, how inflation is driving sustainability in manufacturing, the future of remote regulatory assessments, and more.

CMO Moves: Regulatory catalysts for drug manufacturing-October

Pharmaceutical Technology analyses recent regulatory decisions and trial results that are expected to impact therapy manufacturing plans.

Magazine: Exploring the promise of billion-dollar KRAS drugs

In this issue: the promise of billion-dollar KRAS drugs, exploring nanorobots in drug delivery, foreign investments amplifying the nucleic acid therapeutics field, and more.

CMO Moves: Regulatory catalysts for drug manufacturing-September

Pharmaceutical Technology does a roundup of recent regulatory decisions that impact drugs and the CMOs enlisted to manufacture them.

Foreign investments amplify the nucleic acid therapeutics field

FDI in the nucleic acid therapeutics field grew by 52% in 2021, recording a strong increase since the pandemic slowdown.

Magazine: NICE Makeover: a new look for the UK’s HTAs

In this issue, we take a look at changes at UK’s regulatory body NICE, new therapeutic approaches for prion diseases, and specialty generics production.

CMO Moves: Regulatory catalysts for drug manufacturing—August

Pharmaceutical Technology does a roundup of recent regulatory decisions that impact drugs and the CMOs enlisted to manufacture them.

UK health data collaboration paves the way to study long Covid symptoms

The University of Birmingham’s long Covid study is one of the success stories exploring the global potential of data-driven healthcare, writes Research Fellow Sarah Hughes.